Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2012 Nov 20;107(11):1820-5.
doi: 10.1038/bjc.2012.470. Epub 2012 Oct 18.

VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib

J L Kuiper  1 , J S W Lind, H J M Groen, J Roder, J Grigorieva, H Roder, A M C Dingemans, E F Smit
Affiliations
Clinical Trial

VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib

J L Kuiper et al. Br J Cancer. .

Abstract

Background: The serum proteomic test VeriStrat has been shown to be able to classify advanced non-small cell lung cancer (NSCLC) patients for overall survival (OS) after treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). In this study, VeriStrat was evaluated as a pre-treatment stratification tool in patients with advanced stage NSCLC for treatment with the combination of erlotinib and sorafenib, considering both OS and progression-free survival (PFS) as end points.

Methods: Serum samples from 50 patients treated within the context of a phase II trial of first-line erlotinib and sorafenib were analysed with VeriStrat, a fully locked mass spectrometry-based test that identifies patients likely to have good or poor outcome on EGFR therapy based on eight distinct features in mass spectra. Analysis was performed fully blinded to all clinical data, and then the outcome data were analysed with respect to the obtained serum classifications.

Results: VeriStrat classified pre-treatment samples into two groups, VeriStrat Good and VeriStrat Poor, which were significantly different in OS (hazard ratio (HR) 0.30, log-rank P=0.009) and in PFS (HR 0.40, log-rank P=0.035).

Conclusion: VeriStrat has shown its potential for stratification of unselected, advanced stage NSCLC patients treated in first line with a combination of erlotinib and sorafenib.

PubMed Disclaimer

Conflict of interest statement

J Grigorieva, J Roder and H Roder are employees of Biodesix, the company that performs the VeriStrat proteomic test. The remaining authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Kaplan–Meier plot of OS grouped by VeriStrat classification.
Figure 2
Figure 2
Kaplan–Meier plot of PFS according to VeriStrat classification.
Figure 3
Figure 3
Subgroup analyses by VeriStrat classification. (A) OS for adenocarcinoma patients, (B) PFS for adenocarcinoma patients, (C) OS for ever-smokers and (D) PFS for ever-smokers.
Figure 4
Figure 4
Kaplan–Meier plot of PFS (measured relative to original starting point) grouped by weeks (A) 1 and (B) 3 VeriStrat classification.
See this image and copyright information in PMC

References

    1. Akerley WL, Rich NT, Egbert L, Harker WG, Van Duren T, Smit J, Hoffman JM (2010) Bevacizumab/erlotinib (BEER) as first-line treatment for untreated, advanced non-squamous non-small cell lung cancer (NSNSCLC). J Clin Oncol 28(15 Suppl): e18008
    1. Amann JM, Lee JW, Roder H, Brahmer J, Gonzalez A, Schiller JH, Carbone DP (2010) Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503. J Thorac Oncol 5: 169–178 - PMC - PubMed
    1. Biran H, Friedman N, Neumann L, Pras M, Shainkin-Kestenbaum R (1986) Serum amyloid A (SAA) variations in patients with cancer: correlation with disease activity, stage, primary site, and prognosis. J Clin Pathol 39: 794–797 - PMC - PubMed
    1. Camp ER, Summy J, Bauer TW, Liu W, Gallick GE, Ellis LM (2005) Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res 11: 397–405 - PubMed
    1. Carbone DP, Ding K, Roder H, Tsao M, Shepherd FA, Seymour L (2010a) Serum proteomic prediction of outcomes in advanced NSCLC patients treated with erlotinib or placebo in the NCIC CTG BR.21 trial. J Thorac Oncol 5(Suppl 1)): : abstract number 2030. 2010a

Publication types

MeSH terms